wu-cart-007
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT04984356)
Timeline
Indications
Studied for
- Enteropathy-Associated T-Cell Lymphoma · Phase 1
- Intestinal Neoplasms · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Prolymphocytic, T-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Extranodal NK-T-Cell · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Mycosis Fungoides · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Sezary Syndrome · Phase 1
Mechanism of action
- Tumor necrosis factor receptor superfamily member 9Immunity, passive
TNFRSF9 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06514794 | Phase 2 | Dec 13, 2024 | Wugen, Inc. |
| NCT05377827 | Phase 1 | Dec 31, 2022 | Washington University in St. Louis, Wugen, Inc. |
| NCT04984356 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Wugen, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wugen, Inc. | For profit | 3 | 2 | 2 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1